How to buy Medicenna Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Medicenna Therapeutics stock

Own Medicenna Therapeutics stock in just a few minutes.

Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Medicenna Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MDNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Medicenna Therapeutics share price

Use our graph to track the performance of MDNA stocks over time.

Medicenna Therapeutics shares at a glance

Information last updated 2021-04-14.
52-week range$2.20 - $6.84
50-day moving average $3.97
200-day moving average $4.05
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Medicenna Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Medicenna Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medicenna Therapeutics financials

Gross profit TTM $0
Return on assets TTM -41.1%
Return on equity TTM -71.85%
Profit margin 0%
Book value N/A
Market capitalisation $216.1 million

TTM: trailing 12 months

Shorting Medicenna Therapeutics shares

There are currently 268,568 Medicenna Therapeutics shares held short by investors – that's known as Medicenna Therapeutics's "short interest". This figure is 45.2% up from 184,976 last month.

There are a few different ways that this level of interest in shorting Medicenna Therapeutics shares can be evaluated.

Medicenna Therapeutics's "short interest ratio" (SIR)

Medicenna Therapeutics's "short interest ratio" (SIR) is the quantity of Medicenna Therapeutics shares currently shorted divided by the average quantity of Medicenna Therapeutics shares traded daily (recently around 172158.97435897). Medicenna Therapeutics's SIR currently stands at 1.56. In other words for every 100,000 Medicenna Therapeutics shares traded daily on the market, roughly 1560 shares are currently held short.

However Medicenna Therapeutics's short interest can also be evaluated against the total number of Medicenna Therapeutics shares, or, against the total number of tradable Medicenna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medicenna Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Medicenna Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Medicenna Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medicenna Therapeutics.

Find out more about how you can short Medicenna Therapeutics stock.

Medicenna Therapeutics share dividends

We're not expecting Medicenna Therapeutics to pay a dividend over the next 12 months.

Medicenna Therapeutics share price volatility

Over the last 12 months, Medicenna Therapeutics's shares have ranged in value from as little as $2.195 up to $6.84. A popular way to gauge a stock's volatility is its "beta".

MDNA.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics's is 0.6631. This would suggest that Medicenna Therapeutics's shares are less volatile than average (for this exchange).

Medicenna Therapeutics overview

Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site